3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced/Metastatic Solid Tumors
1
Interventions
Rituximab
67
Cyclophosphamide
41
fludarabine phosphate
17
Etoposide
17
Doxorubicin
17
Vincristine
16
Prednisone
16
Filgrastim
14
Mycophenolic Acid
13
Cyclosporine
13
Lenalidomide
12
Antilymphocyte Serum
12
Gemcitabine
11
Radiotherapy
10
fludarabine
9
Peripheral Blood Stem Cell Transplantation
9
Methotrexate
9
Whole-Body Irradiation
8
Tacrolimus
8
Melphalan
8
Carboplatin
8
Bortezomib
8
venetoclax
7
Dexamethasone
7
Cord Blood Stem Cell Transplantation
7
Busulfan
7
ibritumomab tiuxetan
6
Ifosfamide
6
Flow Cytometry
6
obinutuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Large B-Cell, Diffuse
×
utomilumab
×
Clear all
NCT02951156
2020-12-17
Javelin DLBCL
Pfizer
Phase 3
Terminated
29 enrolled
24 charts